Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Peripheral / undifferentiated SpA Patients Chapter 11 Daily life and follow-up

How Do We Know Treatment Is Working?

Track joint and enthesis findings, function, pain, safety and meaningful change without relying on a single score.

Open accessEvidence reviewed:
All chapters in this collection

Understanding the diagnosis

  1. 1. Peripheral SpA, Undifferentiated SpA and a Working Diagnosis
  2. 2. Joints, Entheses and Dactylitis: Understanding the Peripheral Pattern
  3. 3. How the Diagnosis Is Built
  4. 4. New Symptoms: What Changes the Picture and When Not to Wait

Tests and imaging

  1. 5. Blood Tests and HLA-B27: What They Can and Cannot Tell You
  2. 6. Ultrasound, MRI, X-ray and Joint Aspiration: Choosing the Right Test

Treatment decisions

  1. 7. What Are We Actually Trying to Improve?
  2. 8. NSAIDs, Local Treatment and Conventional DMARDs
  3. 9. When Targeted Therapy Enters the Discussion

Daily life and follow-up

  1. 10. Movement, Feet, Hands, Work and Everyday Load
  2. 11. How Do We Know Treatment Is Working?
  3. 12. Pregnancy, Infection, Surgery and Other Medical Conditions

When the picture changes

  1. 13. Why the Diagnosis May Change
  2. 14. When Pain, Examination, Blood Tests and Imaging Disagree
  3. 15. Remission, Treatment Reduction and Long-Term Outlook

Research and future care

  1. 16. How New Research May Change Treatment

“Better” can mean fewer swollen joints, less pain, a return to work or simply tolerating the medicine. These outcomes matter, but they are not interchangeable. A good review makes it clear which parts of the illness have improved and which still need attention.

Start with a baseline that describes your disease

Before a new treatment, record the active problems as specifically as possible. Which joints are swollen? Is there enthesitis or dactylitis? Which daily activities are limited? Has CRP previously reflected your disease? What adverse effects or safety concerns need monitoring?

The baseline need not become a daily administrative burden. A short dated summary and one or two meaningful functional goals can be more useful than a large spreadsheet with inconsistent measurements. Your clinician supplies the examination; you supply the experience between visits.

Separate tenderness from swelling

Tenderness is important, but it can arise through several mechanisms. Swelling assessed on examination is another piece of information. The two may change at different rates, and both should be interpreted in context.

A falling swollen-joint count may show improvement even when pain remains troublesome. Conversely, feeling less pain does not always establish that all inflammation has resolved. Tell the team about pain medicines, glucocorticoids and other changes that may influence how you feel at the visit.

Look beyond the joints

Enthesis symptoms and whole-digit swelling deserve their own assessment. Skin, eye and bowel disease may require information from other specialists. A joint-focused score cannot stand in for those domains.

This is particularly important when one medicine is expected to help several problems. Improved arthritis does not automatically mean that bowel disease is controlled. A coordinated review should ask whether the treatment is meeting the goals for each organ that matters in your case.

Use blood tests when they are informative

CRP and ESR may contribute to monitoring, but they are not equally useful for every person. If your markers were normal during clearly active joint disease, a normal value during follow-up cannot by itself prove remission. If a marker suddenly rises, infection or another cause may need consideration.

Safety monitoring answers a separate question. A blood count or liver result may help determine whether the medicine remains appropriate even when symptoms improve. Keep the monitoring schedule and know whom to contact if a result is flagged.

What does a composite score add?

A composite score combines several observations to make change easier to track. ASAS-SPARADISE has endorsed DAPSA44 for assessing disease activity related to peripheral arthritis in SpA clinical research. That is a joint-focused application, not a universal measurement of every peripheral SpA manifestation.

Even when a score is useful, it cannot fully describe enthesitis, dactylitis, axial disease, skin, bowel, eye inflammation or your entire life impact. Ask what the score measures and what must be assessed separately. A number is a tool for discussion, not a replacement for it.

Track something you want to regain

Choose a task that can be compared over time: walking a familiar route, dressing, typing or managing a normal work period. Note major contextual changes, such as a new injury or unusually demanding week. Improvement should be interpreted against comparable circumstances.

Fatigue and sleep also deserve discussion. They may improve as inflammation settles, but they can have additional contributors. Persistent fatigue should not automatically trigger escalation of immune treatment without considering the wider picture.

Judge an adequate trial, not a single day

Different medicines need different review intervals. Ask when an early signal of benefit is expected and when the overall trial will be judged. Report side effects, missed doses or access problems because they change what an apparent lack of response means.

One bad day does not necessarily mean treatment has failed. Equally, months of continuing functional loss should not be minimized because one blood result looks reassuring. Bring the trend and the most important change to the review.

The outcome may be to continue treatment, adjust it, investigate persistent inflammation or address another cause of symptoms. Discordant findings explains that reassessment. If control is sustained, remission and treatment reduction addresses the next set of decisions.

Sources and further reading

  1. ASAS-SPARADISE: DAPSA44 for peripheral arthritis in SpA research
  2. ABILITY-2: Randomized adalimumab trial in nonpsoriatic peripheral SpA
  3. MedlinePlus: C-reactive protein test
  4. American College of Rheumatology: Methotrexate

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Peripheral SpASpondyloarthritis